黑料吃瓜群网

A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the oesophagus and stomach in a large patient trial presented at the .^[1]

Together, stomach and oesophageal cancer account for around 1.4 million new cancer diagnoses each year worldwide.^[2] Both tend to be diagnosed late, because the symptoms are ambiguous, meaning the five-year survival rate for these two types of cancer is only 15%.

The new research, involving more than 300 patients, showed that the test could diagnose cancer with an overall accuracy of 85%.

Dr Sheraz Markar, an NIHR Clinical Trials Fellow from , under the supervision of Professor George Hanna, told the Congress: 鈥淎t present the only way to diagnose oesophageal cancer or stomach cancer is with endoscopy. This method is expensive, invasive and has some risk of complications.

鈥淎 breath test could be used as a non-invasive, first-line test to reduce the number of unnecessary endoscopies. In the longer term this could also mean earlier diagnosis and treatment, and better survival.鈥�

The trial was based on the results of previous research that suggested differences in the levels of specific chemicals (butyric, pentanoic and hexanoic acids; butanal; and decanal) between patients with stomach or oesophageal cancer and patients with upper gastrointestinal symptoms without cancer. The new research aimed to test whether this 鈥榗hemical signature鈥� that seemed to typify cancer could be the basis of a diagnostic test.

In the new study, the research team collected breath samples from 335 people at , Imperial College Healthcare NHS Trust; ; and the . Of these, 163 had been diagnosed with stomach or oesophageal cancer and 172 showed no evidence of cancer when they had an endoscopy.

All the samples were analysed with a technique called selected ion flow-tube mass spectrometry, which is able to accurately measure small amounts of different chemicals in mixtures of gases such as breath.

Researchers measured the levels of the five chemicals in each sample to see which ones matched to the 鈥榗hemical signature鈥� that indicated cancer.

The results showed that the test was 85% accurate overall, with a sensitivity of 80% and a specificity of 81%. This means that not only was the breath test good at picking up those who had cancer (sensitivity), it was also good at correctly identifying who did not have cancer (specificity).

Dr Markar said: 鈥淏ecause cancer cells are different to healthy ones, they produce a different mixture of chemicals. This study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach, and which do not. However, these findings must be validated in a larger sample of patients before the test could be used in the clinic.鈥�

Over the next three years, the researchers will continue with a larger trial, using the test with patients who are being given an endoscopy for gastrointestinal symptoms but not yet diagnosed with cancer. This will assess the ability of the test to pick up cases within a group that is likely to contain only a small percentage of cancers.

The team is also working on breath tests for other types of cancer, such as colorectal and pancreatic, which could be used as first-line tests in general practice surgeries.

[1] The European Cancer Congress is the only truly multidisciplinary oncology congress in the world. It is organised by the European CanCer Organisation (ECCO), a not-for-profit federation of 25 member societies, representing over 80,000 professionals working in cancer.
[2] According to Cancer Today, oesophageal cancer is the eighth most common cancer in the world with an estimated 456,000 new cases in 2012, and causing 400,000 deaths a year. For stomach cancer, there are 952,000 new cases and 723,000 deaths. Cancer Today (formerly Globocan): http://gco.iarc.fr/today/home.
[3] Dr Sheraz Markar was funded by the National Institute of Health Research (NIHR). This research was also supported by the NIHR Diagnostic Evidence Co-operative London at Imperial College Healthcare NHS Trust.